Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Evolus
< Previous
1
2
Next >
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
November 07, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
November 06, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in November Investor Conferences
November 01, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Third Quarter 2023 Results
October 25, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
October 25, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in September Conferences
August 29, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Inducement Grants for New Chief Marketing Officer
August 23, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
August 21, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
August 08, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Second Quarter 2023 Results and Provides Business Update
August 02, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
July 27, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Second Quarter 2023 Results and Provide Business Update
July 19, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
June 29, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
June 22, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
June 08, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports First Quarter 2023 Results and Provides Business Update
May 09, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 08, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the Barclays Global Healthcare Conference
February 28, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
February 22, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Not Affected by Recent Korean Court Ruling
February 10, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
January 28, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Receives Regulatory Approval for Nuceiva® in Australia
January 23, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
January 23, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
January 18, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Extends Term of Credit Facility with Pharmakon Advisors
December 08, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in November Conferences
November 02, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Third Quarter 2022 Results and Provide Business Update
October 25, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.